NL0010832176
Impact Score
argenx is a global immunology company developing antibody-based therapies for the treatment of severe autoimmune diseases and cancer.
Impact Score
Metric | Value | Unit | Year | PDF Name | PDF Page | |
---|---|---|---|---|---|---|
CEO-to-Employee Pay Ratio | ||||||
11 944 835 | $ | 2023 | entire-argenx-ar23.pdf | 181 | ||
1 148 | employees | 2023 | entire-argenx-ar23.pdf | 268 | ||
529 377 | thousands of $ | 2023 | entire-argenx-ar23.pdf | 329 | ||
Tim Van Hauwermeiren | 2023 | entire-argenx-ar23.pdf | 166 | |||
Employee turnover rate | ||||||
7 | % | 2023 | ESG_Report_2023_argenx.pdf | 27 | ||
Gender Pay Gap | ||||||
2,1 | % | 2023 | ESG_Report_2023_argenx.pdf | 32 | ||
Glass Ceiling | ||||||
662 | Number | 2023 | ESG_Report_2023_argenx.pdf | 57 | ||
1 148 | employees | 2023 | entire-argenx-ar23.pdf | 268 | ||
Greenhouse Gas Emissions | ||||||
378 | tCO2e | 2023 | ESG_Report_2023_argenx.pdf | 53 | ||
1 148 | employees | 2023 | entire-argenx-ar23.pdf | 268 | ||
183 | tCO2e | 2023 | ESG_Report_2023_argenx.pdf | 53 | ||
Harassment and Discrimination at the Workplace | ||||||
Yes | 2023 | entire-argenx-ar23.pdf | 365 | |||
Yes | 2023 | Code_of_Business_Conduct_and_ethics.pdf | 35 | |||
Yes | 2023 | entire-argenx-ar23.pdf | 222 | |||
Yes | 2023 | entire-argenx-ar23.pdf | 366 | |||
Supply Chain | ||||||
183 | tCO2e | 2023 | ESG_Report_2023_argenx.pdf | 53 | ||
432 786 | tCO2e | 2023 | ESG_Report_2023_argenx.pdf | 53 | ||
1 148 | employees | 2023 | entire-argenx-ar23.pdf | 268 | ||
378 | tCO2e | 2023 | ESG_Report_2023_argenx.pdf | 53 | ||
Women on the Board | ||||||
9 | Management | 2023 | entire-argenx-ar23.pdf | 166 | ||
9 | Number | 2023 | entire-argenx-ar23.pdf | 152 | ||
2 | Management | 2023 | entire-argenx-ar23.pdf | 166 | ||
3 | Number | 2023 | entire-argenx-ar23.pdf | 152 | ||
Women in Management | ||||||
39 | % | 2023 | entire-argenx-ar23.pdf | 151 |